Fiche publication
Date publication
février 2021
Journal
EJHaem
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier
,
Pr DECONINCK Eric
,
Pr GARNACHE-OTTOU Francine
,
Pr PHILIPPE Laurent
,
Dr DAGUINDAU Etienne
,
Dr KROEMER Marie
,
Dr ANGELOT-DELETTRE Fanny
Tous les auteurs :
Poussard M, Philippe L, Fredon M, Bôle-Richard E, Biichle S, Renosi F, Perrin S, Kroemer M, Limat S, Bonnefoy F, Daguindau E, Deconinck E, Gruson B, Saas P, Adotévi O, Garnache-Ottou F, Angelot-Delettre F
Lien Pubmed
Résumé
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these therapies, the influence of one on the other has to be explored. We set up a model to test the combination of polychemotherapy - named methotrexate, idarubicine, dexamethasone, and L-asparaginase (MIDA) - and CD123 CAR-T cell therapy. We showed that CD123 CAR-T cells exert the same effect on BPDCN models alone, or after MIDA regimen. These data support a preclinical rationale to use immunotherapy after a treatment with polychemotherapy for BPDCN patients.
Mots clés
T cells, acute leukemia, cell therapy, chemotherapy, immunology
Référence
EJHaem. 2021 02;2(1):125-130
